FTE Payments. A. In addition to the payment due pursuant to the other paragraphs of this Section 4, PIONEER will pay to MAXYGEN, for the [*******] FTEs set forth in (P)2.1A(b), a non-refundable amount of [*******] per year during [*******] of the Research Term, commencing as of the Effective Date.
B. Payments due pursuant to (P)4.13 above shall be made in advance, on or before the first day of each calendar quarter, with the first and last payments prorated in the event that the Effective Date is not the first day of a calendar quarter. In the event that the parties agree to a different Staffing Level for any given calendar quarter as set forth in (P)2.1A(b), the payment set forth in this (P)4.13 shall be pro-rated accordingly based on a level of funding of [*******] per year per FTE.
FTE Payments. During the Term, Agrigenetics shall pay EPS each year the applicable FTE Rate (as defined below) for each FTE performing work under the Research Plan (excluding [ * ]) who is an employee of EPS, and Agrigenetics shall also pay EPS a one-time payment during the first Contract Year of [ * ] for [ * ]. The FTE Rate shall be deemed to include all salaries, benefits and direct and indirect costs of such FTEs, but shall not be deemed to include any Facility Expenses or capital expenditures, which shall be separately reimbursed by Agrigenetics pursuant to Sections 6.2 and 6.
FTE Payments. Based on the budget set forth in each Joint Research Plan, Calico shall pay C4T in arrears for FTEs used by C4T in the preceding Calendar Quarter pursuant to such Joint Research Plan. C4T shall provide to Calico an invoice, on a Joint Research Plan-by-Joint Research Plan basis, setting forth the number of actual FTEs used, the FTE Rate and the amount payable. Calico shall pay such invoices within [***] after receipt of such invoice from C4T.
FTE Payments. (a) The First FTE Payment shall be made by Lilly to Arena within thirty (30) days after the Effective Date. Any reconciliation of the First FTE Payment shall be made in accordance with Section 2.2(c).
(b) For all other FTE payments, Lilly shall pay to Arena an Annual FTE Payment for Arena FTEs in the amount of ********************************** ********** for each FTE. Such Annual FTE Payment shall be made quarterly within thirty (30) days of the receipt of an invoice for the previous Quarter during which the FTE work was performed, in the amount of ******************************* ********* for each FTE for each of such Quarters ("Quarterly FTE Payment").
(c) FTE Payments made hereunder shall be non-creditable and non-refundable, provided that all Arena FTE time paid for by Lilly hereunder is devoted to tasks associated with the Project as agreed to by the Parties hereunder. In the event that it is determined under Section 2.4 that one or more Arena FTEs did not devote the time
FTE Payments. 4.4.1 In addition to the other payments due pursuant to this Article 4, DOW will pay to DIVERSA a nonrefundable amount of Three Million Six Hundred Thousand (US$3,600,000) Dollars per year for the 12 FTEs set forth in Section 2.1.1
FTE Payments. Novartis will reimburse Cerulean at the FTE Rate for up to five FTEs engaged in Collaboration activities, as set forth in the Research Plans (including the extension of the Research Term for one or more of the Programs as contemplated by Section 2.1.2). Reimbursement will be made once per Calendar Quarter, in arrears, within [**] days after receipt of an Invoice including a summary of the FTE activities in such Calendar Quarter. For the avoidance of doubt, the FTE Rate includes all [**].
FTE Payments. 4.4.1 In addition to the other payments due pursuant to this Article 4, TDCC shall pay to DIVERSA:
(a) a noncontingent and nonrefundable amount of [***] per FTE for all FTEs for the Project Field as specified in the Work Plans from the Effective Date [***]; and
(b) for [***] a noncontingent and nonrefundable amount per FTE equal to DIVERSA's then applicable FTE rate ("Standard FTE Rate") in effect on [***].
(c) It is expressly agreed by the Parties that [***]. Unless agreed to in writing by DIVERSA, which agreement may be given or withheld in DIVERSA's sole and absolute discretion, TDCC will [***].
FTE Payments. 4.4.1 In addition to the other payments due pursuant to this Article 4, DOW will pay to DIVERSA a nonrefundable amount of [*****] Dollars per year for the [*****] FTEs set forth in Section 2.1.1
FTE Payments. The “FTE Rate” shall be $[***] per FTE (as adjusted as set forth below) and includes all salary, employee benefits, incidental materials and other expenses including support staff and overhead for or associated with an FTE incurred by such FTEs in performance of the Research Plan, Development Plan or Commercialization Plan (unless a different FTE Rate is specified elsewhere herein *** Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions.
1. After the expiration of the Research Term, any unused portion of the FTE funding provided by Amgen pursuant to this Section shall be, at Amgen’s option, promptly reimbursed to Amgen or credited against amounts otherwise payable by Amgen hereunder. In addition, the last calendar [***] during the Research Term shall be appropriately prorated. With respect to FTEs devoted to activities to be performed by CK pursuant to Section 5.5.4, within [***] ([***]) [***] after receipt of an invoice from CK therefor, Amgen shall pay to CK an amount equal to the FTE Rate times the number of FTEs actually dedicated to such activities in such [***].
FTE Payments. Assuming MethylGene remains in compliance with its FTE obligations set forth in the R&D Plan as well as its other funding obligations under this Article V, and subject to the last sentence of Section 6.1.4, EVP shall pay MethylGene US$[…***…] for […***…] FTEs (the “FTE Payments”), as follows: (1) US$[…***…] on or before […***…] from the Effective Date, (2) US$[…***…] on or before […***…], (3) US$[…***…] on or before […***…] and (4) US$[…***…] on or before […***…]. Such FTE Payments shall not be deemed Research and Development Costs of EVP.